title: [A case of effective combination therapy with docetaxel, cyclophosphamide and trastuzumab as primary systemic therapy for locally advanced HER2-positive breast cancer].
abstract: We experienced a case of locally advanced breast cancer achieving a significant improvement by using a combination of docetaxel(DOC), cyclophosphamide(CPA)and trastuzumab as a primary systemic therapy.The patient was a 54-year-old woman suffering from a right breast mass, who was referred to our hospital and diagnosed with HER2-positive breast cancer with subclavicular lymph nodes metastases.The combination therapy of DOC(75 mg/m / 2), CPA(600 mg/m2)and trastuzumab(loading dose 8 mg/kg, then 6 mg/kg)for 6 courses at q3 week intervals, was started as the primary systemic therapy. After 6 courses of treatment, a right modified radical mastectomy was performed.There were a little breast cancer cells in the breast, and no axillary lymph node metastases.The combination chemotherapeutic regime with DOC, CPA and trastuzumab seems to be useful for treatment of HER2-positive breast cancer.
authors.affiliation: Dept. of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine.
authors.forename: Naruhiko
authors.initials: N
authors.lastname: Mizuta
authors.forename: Asako
authors.initials: A
authors.lastname: Nishiyama
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Mizuta
authors.forename: Mariko
authors.initials: M
authors.lastname: Goto
authors.forename: Aya
authors.initials: A
authors.lastname: Imai
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Umeda
authors.forename: Midori
authors.initials: M
authors.lastname: Morita
authors.forename: Koichi
authors.initials: K
authors.lastname: Sakaguchi
authors.forename: Eiichi
authors.initials: E
authors.lastname: Konishi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Taguchi
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003520:Cyclophosphamide; D000077143:Docetaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab